Levin Capital Strategies L.P. Buys New Shares in Quanterix Co. (NASDAQ:QTRX)

Levin Capital Strategies L.P. bought a new stake in Quanterix Co. (NASDAQ:QTRX) in the 4th quarter, Holdings Channel reports. The firm bought 15,000 shares of the company’s stock, valued at approximately $159,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Peapack Gladstone Financial Corp bought a new position in shares of Quanterix in the third quarter valued at $131,000. Intech Investment Management LLC bought a new position in shares of Quanterix in the third quarter valued at $170,000. Tallon Kerry Patrick bought a new position in shares of Quanterix in the fourth quarter valued at $169,000. GSA Capital Partners LLP bought a new position in shares of Quanterix in the third quarter valued at $258,000. Finally, Janney Capital Management LLC grew its stake in shares of Quanterix by 33.6% in the third quarter. Janney Capital Management LLC now owns 23,553 shares of the company’s stock valued at $305,000 after buying an additional 5,930 shares in the last quarter. 86.48% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, TD Cowen raised their target price on shares of Quanterix from $13.50 to $16.00 and gave the company a “hold” rating in a research note on Wednesday, November 13th.

Quanterix Price Performance

Shares of Quanterix stock opened at $7.59 on Monday. The business has a fifty day simple moving average of $9.30 and a two-hundred day simple moving average of $11.41. Quanterix Co. has a 1 year low of $7.30 and a 1 year high of $29.70. The company has a market capitalization of $292.40 million, a price-to-earnings ratio of -7.16 and a beta of 1.33.

Quanterix (NASDAQ:QTRX) last announced its quarterly earnings results on Monday, December 23rd. The company reported ($0.22) earnings per share (EPS) for the quarter. Quanterix had a negative net margin of 30.12% and a negative return on equity of 11.74%. As a group, equities analysts anticipate that Quanterix Co. will post -0.98 earnings per share for the current fiscal year.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.